The egfr/mir-338-3p/eya2 axis controls breast tumor growth and lung metastasis

Cell Death and Disease

Volumn 8, Issue 7, 2017, Pages

  Liang, Yingchun ^a   Xu, Xiaojie ^a   Wang, Tao ^b   Li, Ying ^a,c   You, Wenye ^a,c   Fu, Jing ^a   Liu, Yang ^a,c   Jin, Shuai ^a,c   Ji, Quanbo ^a,c   Zhao, Wei ^c   Song, Qi ^c   Li, Ling ^a   Hong, Tian ^a   Huang, Junjian ^a   Lyu, Zhaohui ^c   Ye, Qinong ^a  

^a BEIJING INSTITUTE OF BIOTECHNOLOGY   (China)

^b Beijing 307 Hospital   (China)

^c CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EYA2 PROTEIN, MOUSE; GEFITINIB; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MICRORNA; MIRN338 MICRORNA, MOUSE; NUCLEAR PROTEIN; PROTEIN TYROSINE PHOSPHATASE; QUINAZOLINE DERIVATIVE; SIGNAL PEPTIDE;

ADULT; AGED; ALLOTRANSPLANTATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BREAST TUMOR; DOWN REGULATION; DRUG EFFECT; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENETICS; HUMAN; LUNG TUMOR; METABOLISM; MIDDLE AGED; MOUSE; PATHOLOGY; SECONDARY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; DOWN-REGULATION; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICRORNAS; MIDDLE AGED; NUCLEAR PROTEINS; PROTEIN TYROSINE PHOSPHATASES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TRANSPLANTATION, HOMOLOGOUS;

EID: 85032700250     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2017.325     Document Type: Article

References (48)

1. Zhang H, Berezov A, Wang Q, Zhang G, Drebin J, Murali R et al. ErbB receptors: from oncogenes to targeted cancer therapies. J Clin Invest 2007; 117: 2051–2058.
2. She QB, Solit DB, Ye Q, O'Reilly KE, Lobo J, Rosen N. The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. Cancer Cell 2005; 8: 287–297.
3. Efferth T. Signal transduction pathways of the epidermal growth factor receptor in colorectal cancer and their inhibition by small molecules. Curr Med Chem 2012; 9: 5735–5744.
4. Rocha-Lima CM, Soares HP, Raez LE, Singal R. EGFR targeting of solid tumors. Cancer Control 2007; 4: 295–304.
5. Masuda H, Zhang D, Bartholomeusz C, Doihara H, Hortobagyi GN, Ueno NT. Role of epidermal growth factor receptor in breast cancer. Breast Cancer Res Treat 2012; 136: 331–345.
6. Mitsudomi T, Yatabe Y. Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. FEBS J 2010; 277: 301–308.
7. Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, Chirieac LR et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008; 27: 4702–4711.
8. Rimawi MF, Shetty PB, Weiss HL, Schiff R, Osborne CK, Chamness GC et al. Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes. Cancer 2010; 116: 1234–1242.
9. Dhawan P, Ahmad R, Chaturvedi R, Smith JJ, Midha R, Mittal MK et al. Claudin-2 expression increases tumorigenicity of colon cancer cells: role of epidermal growth factor receptor activation. Oncogene 2011; 30: 3234–3247.
10. Smith JS, Tachibana I, Passe SM, Huntley BK, Borell TJ, Iturria N et al. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst 2001; 93: 1246–1256.
11. Tebbutt N, Pedersen MW, Johns TG. Targeting the ERBB family in cancer: couples therapy. Nat Rev Cancer 2013; 13: 663–673.
12. Steeg PS. Targeting metastasis. Nat Rev Cancer 2016; 16: 201–128.
13. Calin GA, Croce CM. Chromosomal rearrangements and microRNAs: a new cancer link with clinical implications. J Clin Invest 2007; 117: 2059–2066.
14. Chang YS, Chen WY, Yin JJ, Sheppard-Tillman H, Huang J, Liu YN. EGF receptor promotes prostate cancer bone metastasis by downregulating miR-1 and activating TWIST1. Cancer Res 2015; 75: 3077–3086.
15. Sun J, Feng X, Gao S, Xiao Z. microRNA-338-3p functions as a tumor suppressor in human non-small-cell lung carcinoma and targets Ras-related protein. Mol Med Rep 2015; 11: 1400–1406.
16. Blevins MA, Towers CG, Patrick AN, Zhao R, Ford HL. The SIX1-EYA transcriptional complex as a therapeutic target in cancer. Expert Opin TherTargets 2015; 19: 213–225.
17. Fu J, Xu X, Kang L, Zhou L, Wang S, Lu J et al. miR-30a suppresses breast cancer cell proliferation and migration by targeting EYA2. Biochem Biophys Res Commun 2014; 45: 314–219.
18. Muraoka RS, Dumont N, Ritter CA, Dugger TC, Brantley DM, Chen J et al. Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. J Clin Invest 2002; 109: 1551–1559.
19. Pulaski BA, Ostrand-Rosenberg S. Mouse 4T1 breast tumor model. Curr Protoc Immunol 2001; 20: 202–212.
20. Garofalo M, Romano G, Di Leva G, Nuovo G, Jeon YJ, Ngankeu A et al. EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat Med 2011; 18: 74–82.
21. Schlessinger J. Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell 2002; 110: 669–672.
22. Peng XH, Karna P, Cao Z, Jiang BH, Zhou M, Yang L. Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1alpha signal pathways increases resistance to apoptosis by up-regulating survivin gene expression. J Biol Chem 2006; 281: 25903–25914.
23. Pore N, Jiang Z, Gupta A, Cerniglia G, Kao GD, Maity A. EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms. Cancer Res 2006; 66: 3197–3204.
24. Xu H, Zhao L, Fang Q, Sun J, Zhang S, Zhan C et al. MiR-338-3p inhibits hepatocarcinoma cells and sensitizes these cells to sorafenib by targeting hypoxia-induced factor 1α. PLoS One 2014; 9: e115565.
25. Verma N, Keinan O, Selitrennik M, Karn T, Filipits M. Lev s. PYK2 sustains endosomal-derived receptor signalling and enhances epithelial-to-mesenchymal transition. Nat Commun 2015; 6: 6064.
26. Lu Z, Jiang G, Blume-Jensen P, Hunter T. Epidermal growth factor-induced tumor cell invasion and metastasis initiated by dephosphorylation and downregulation of focal adhesion kinase. Mol Cell Biol 2001; 21: 4016–4031.
27. Jin Y, Zhao M, Xie Q, Zhang H, Wang Q, Ma Q. MicroRNA-338-3p functions as tumor suppressor in breast cancer by targeting SOX4. Int J Oncol 2015; 47: 1594–1602.
28. Huang N, Wu Z, Lin L, Zhou M, Wang L, Ma H et al. MiR-338-3p inhibits epithelial-mesenchymal transition in gastric cancer cells by targeting ZEB2 and MACC1/Met/Akt signaling. Oncotarget 2015; 6: 15222–15234.
29. Wen C, Liu X, Ma H, Zhang W, Li H. miR-338-3p suppresses tumor growth of ovarian epithelial carcinoma by targeting Runx2. Int J Oncol 2015; 46: 2277–2285.
30. Xue Q, Sun K, Deng HJ, Lei ST, Dong JQ, Li GX. MicroRNA-338-3p inhibits colorectal carcinoma cell invasion and migration by targeting smoothened. Jpn J Clin Oncol 2014; 44: 13–21.
31. Peng Y, Liu YM, Li LC, Wang LL, Wu XL. MicroRNA-338 inhibits growth, invasion and metastasis of gastric cancer by targeting NRP1 expression. PLoS One 2014; 9: e94422.
32. Chen JS, Liang LL, Xu HX, Chen F, Shen SL, Chen W et al. miR-338-3p inhibits epithelial-mesenchymal transition and metastasis in hepatocellular carcinoma cells. Oncotarget 2016.
33. Li Y, Chen P, Zu L, Liu B, Wang M, Zhou Q. MicroRNA-338-3p suppresses metastasis of lung cancer cells by targeting the EMT regulator Sox4. Am J Cancer Res 2016; 6: 127–140.
34. Zhang L, Yang N, Huang J, Buckanovich RJ, Liang S, Barchetti A et al. Transcriptional coactivator Drosophila eyes absent homologue 2 is up-regulated in epithelial ovarian cancer and promotes tumor growth. Cancer Res 2005; 65: 925–932.
35. Farabaugh SM, Micalizzi DS, Jedlicka P, Zhao R, Ford HL. EYA2 is required to mediate the pro-metastatic functions of Six1 via the induction of TGF-β signaling, epithelial-mesenchymal transition, and cancer stem cell properties. Oncogene 2012; 31: 552–562.
36. Gao T, Zheng S, Li Q, Ran P, Sun L, Yuan Y et al. Aberrant hypomethylation and overexpression of the eyes absent homologue 2 suppresses tumor cell growth of human lung adenocarcinoma cells. Oncol Rep 2015; 34: 2333–2342.
37. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133: 704–715.
38. Weigelt B, Peterse JL, van 't Veer LJ. Breast cancer metastasis: markers and models. Nat Rev Cancer 2005; 5: 591–602.
39. Herbst RS, Fukuoka M, Baselga J. Gefitinib–a novel targeted approach to treating cancer. Nat Rev Cancer 2004; 4: 956–965.
40. Modi S, D'Andrea G, Norton L, Yao TJ, Caravelli J, Rosen PP et al. A phase I study of cetuximab/paclitaxel in patients with advanced-stage breast cancer. Clin Breast Cancer 2006; 7: 270–277.
41. Shepard HM, Brdlik CM, Schreiber H. Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR family. J Clin Invest 2008; 118: 3574–3581.
42. Zhao B, Wang L, Qiu H, Zhang M, Sun L, Peng P et al. Mechanisms of resistance to anti-EGFR therapy in colorectal cancer. Oncotarget 2017; 8: 14012.
43. Krueger AB, Drasin DJ, Lea WA, Patrick AN, Patnaik S, Backos DS et al. Allosteric inhibitors of the EYA2 phosphatase are selective and inhibit EYA2-mediated cell migration. J Biol Chem 2014; 289: 16349–16361.
44. Park H, Ryu SE, Kim SJ. Structure-based de novo design of EYA2 phosphatase inhibitors. J Mol Graph Model 2012; 38: 382–388.
45. Wang H, Li S, Li H, Li C, Guan K, Luo G et al. SGEF enhances EGFR stability through delayed EGFR trafficking from early to late endosomes. Carcinogenesis 2013; 34: 1976–1783.
46. Chang Y, Liu C, Yang J, Liu G, Feng F, Tang J et al. miR-20a triggers metastasis of gallbladder carcinoma. J Hepatol 2013; 59: 518–527.
47. Zhang H, Xie X, Zhu X, Zhu J, Hao C, Lu Q, Ding L et al. Stimulatory cross-talk between NFAT3 and estrogen receptor in breast cancer cells. J Biol Chem 2005; 280: 43188–43197.
48. Liu ZH, Hu JL, Liang JZ, Zhou AJ, Li MZ, Yan SM et al. Far upstream element-binding protein 1 is a prognostic biomarker and promotes nasopharyngeal carcinoma progression. Cell Death Dis 2015; 6: e1920.